Key result
Immune checkpoint inhibitor myocarditis carries ~50% case fatality in severe presentations.
Why the study?
Immune checkpoint inhibitor-induced myocarditis is a potentially life-threatening complication of cancer treatment with a case-fatality rate approaching 50% in severe cases, and its prevalence may increase as ICI prescriptions rise.
Answers are grounded in this paper and cite their sources.
Highlights that immune checkpoint inhibitor-induced myocarditis is an increasingly prevalent, autoimmune-mediated complication of cancer therapy with a case-fatality rate up to 50% in severe cases.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Thuny et al. (2021) conducted a review in Immune checkpoint inhibitor-induced myocarditis. Immune checkpoint inhibitors was evaluated. Immune checkpoint inhibitor-induced myocarditis is a potentially life-threatening autoimmune complication of cancer therapy with a case-fatality rate approaching 50% in severe cases.
Synapse has enriched 10 related papers. Consider them for comparative context: